{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?ddpModified.=2021-12-06T22%3A05%3A56.587Z", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?ddpModified.=2021-12-06T22%3A05%3A56.587Z", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?ddpModified.=2021-12-06T22%3A05%3A56.587Z&_metadata=all", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&ddpModified.=2021-12-06T22%3A05%3A56.587Z", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?ddpModified.=2021-12-06T22%3A05%3A56.587Z", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?ddpModified.=2021-12-06T22%3A05%3A56.587Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1385186", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1385186/answer", "answerText" : {"_value" : "<p>Intellectual Property rights have been critical in underpinning innovators\u2019 confidence to form over 300 partnerships - an unprecedented number - which have made real, positive impacts on vaccine delivery; examples include AstraZeneca and the Serum Institute of India, and Pfizer-BioNTech and BIOVAC in South Africa. These examples show what is possible when the right partners work together and share technology.<\/p><p> <\/p><p>While we must continue to ensure vaccine production needs are met globally, the WHO news release of 7 October made it clear that, \u201cWith global vaccine production now at nearly 1.5 billion doses per month, there is sufficient vaccine from a supply perspective to achieve global vaccination targets\u201d. We must therefore also focus on issues of distribution and delivery to successfully vaccinate the globe.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4336", "label" : {"_value" : "Biography information for Lord Callanan"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Callanan"}
        , "dateOfAnswer" : {"_value" : "2021-12-20", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-12-20T13:11:13.07Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-12-06", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government what assessment they have made of calls by the President of the United States and NGOs to waive intellectual property rights on COVID-19 vaccines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2018", "label" : {"_value" : "Biography information for Lord Hylton"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Hylton"}
      ], "uin" : "HL4715"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}